Find My Journal

JS

Jef De Schutter

Independent Researcher

32

Publications

3,183

Citations

9

H-Index

9

i10-Index

0

2yr Mean Cite

-

Cite/Paper

Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

Treated with Salvage Cetuximab / Panitumumab Monotherapy Improved Outcome in Patients with Metastatic Colorectal Cancer Predicts KRAS microRNA-Binding Site Polymorphism in let-7 A Updated

Z. Saridaki, J. Weidhaas, H. Lenz, P. Laurent-Puig, B. Jacobs - Unknown Venue, 2014

Cited by 0 Semantic Scholar

Effect of EGFR inhibition on HER3/PI3K activation by feedback induction of ErbB heterodimers in cetuximab-sensitive colon cancer cells.

B. Jacobs, L. Vecchione, N. Hoe, J. Schutter, B. Biesmans - Unknown Venue, 2013

Cited by 0 Semantic Scholar

Clinical Biomarkers in Oncology

W. Roock, B. Biesmans, J. Schutter, S. Tejpar - Molecular Diagnosis & Therapy, 2012

Cited by 30 Semantic Scholar

P1.28 Dusp4 Expression as A Marker of Heterogeneous Signaling in Colorectal Cancer Patients OA

V. Vriendt, W. Roock, A. D. Narzo, S. Tian, B. Biesmans - Unknown Venue, 2012

Cited by 10 Semantic Scholar

Clinical Biomarkers in Oncology Focus on Colorectal Cancer

W. Roock, B. Biesmans, J. Schutter, S. Tejpar - Unknown Venue, 2012

Cited by 26 Semantic Scholar

Reply to C. Cremolini et al OA

B. Jacobs, W. Roock, H. Piessevaux, B. Biesmans, J. Schutter - Unknown Venue, 2010

Cited by 0 Semantic Scholar

Predictors of Benefit in Colorectal Cancer Treated With Cetuximab: Are We Getting "Lost in TranslationAL"? Reply

B. Jacobs, H. Piessevaux, W. Roock, B. Biesmans, J. Schutter - Unknown Venue, 2010

Cited by 0 Semantic Scholar

PIK 3 CAMutations Are Not aMajor Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

H. Prenen, J. Schutter, B. Jacobs, W. Roock, B. Biesmans - Unknown Venue, 2009

Cited by 1 Semantic Scholar

PIK3CA mutations do not confer resistance to the EGFR-inhibitor cetuximab in chemorefractory metastatic colorectal cancer

W. Roock, J. Schutter, H. Prenen, B. Jacobs, B. Biesmans - Unknown Venue, 2009

Cited by 1 Semantic Scholar

DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease

W. Roock, M. Janssens, B. Biesmans, B. Jacobs, J. Schutter - Unknown Venue, 2008

Cited by 4 Semantic Scholar

Research Topics

Colorectal Cancer Treatments and Studies (32) Lung Cancer Treatments and Mutations (11) Hepatocellular Carcinoma Treatment and Prognosis (10) Cancer Genomics and Diagnostics (8) Cancer Immunotherapy and Biomarkers (7)

Affiliations

Merck (Germany)

DE 2007 - 2007

Universitair Ziekenhuis Leuven

BE 2006 - 2006

Ghent University

BE 2007 - 2007

Center for Human Genetics

US 2009 - 2009

KU Leuven

BE 2013 - 2006

External Profiles

OpenAlex Profile Semantic Scholar Profile Google Scholar

Share Profile

Back to Researchers